文献速递白血病造血干细胞移植与细胞治疗

接受替沙基仑赛治疗的儿童患者中持续性重度中性粒细胞减少的特征与预测

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.
PubMed 文献 · Blood Adv · 2025-01-01

这项多机构研究纳入326例接受替沙基仑赛治疗的儿童和年轻成人B细胞急性淋巴细胞白血病患者,在训练队列(144例可评估)和验证队列(141例可评估)中描述持续性重度中性粒细胞减少(PSN)的发生率和结局并开发预测风险评分。训练队列PSN发生率为15.3%,验证队列为21%;PSN与较差的总生存、无复发生存、更高的非复发死亡及30天内感染风险相关。CytoRisk评分在验证队列中区分PSN的曲线下面积为0.90。

要点

  • PSN定义为中性粒细胞绝对计数<0.5×10³/μL持续≥30天,训练队列发生率15.3%,验证队列21%。
  • PSN与较差的总生存(P<.001)、无复发生存(P=.01)、更高的非复发死亡(P=.003)及30天内感染风险(P=.03)相关。
  • CytoRisk评分在验证队列中区分PSN的曲线下面积为0.90,特异度93%、敏感度71%。

核心结论

  • CytoRisk评分或可用于预先识别PSN及总体结局较差风险最高的患者。

研究设计与样本

  • 多机构研究,通过儿童真实世界CAR联盟纳入326例接受替沙基仑赛治疗的儿童和年轻成人B细胞急性淋巴细胞白血病患者,训练队列144例可评估,验证队列141例可评估。

主要发现

  • PSN定义为中性粒细胞绝对计数<0.5×10³/μL持续≥30天,训练队列发生率为15.3%,验证队列为21%。
  • PSN与较差的总生存(P<.001)、无复发生存(P=.01)、更高的非复发死亡(P=.003)及30天内感染风险增加(P=.03)相关。
  • 多变量惩罚回归分析识别出PSN的关键风险因素,包括输注前C反应蛋白和骨髓疾病负荷、输注后铁蛋白峰值及重度细胞因子释放综合征的发生,并用于构建CytoRisk评分。
  • 在验证队列中,CytoRisk评分区分有无PSN的曲线下面积为0.90,特异度93%、敏感度71%、阳性预测值74%、阴性预测值92%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematotoxicity is the most frequent severe toxicity after chimeric antigen receptor T-cell (CAR-T) therapy. However, limited data exist on risk factors and outcomes for hematotoxicity for children and young adults (CAYAs) with B-acute lymphoblastic leukemia treated with tisagenlecleucel. We conducted a multi-institutional study involving 326 CAYAs, with 144 evaluable in an initial training cohort and 141 evaluable in a validation cohort, through the Pediatric Real-World CAR Consortium to characterize the incidence and outcomes of prolonged severe neutropenia (PSN) and to develop a predictive risk score for PSN, tailored for use in this population. The incidence of PSN, defined as an absolute neutrophil count of <0.5 x 103 cells per μL for ≥30 days, was 15.3% in the initial training cohort and 21% in the validation cohort. Development of PSN was associated with inferior overall survival (P < .001), relapse-free survival (P = .01), higher nonrelapse mortality (P = .003), and a greater risk of infections within 30 days (P = .03). Multivariable penalized regression analysis identified key risk factors for PSN, which included preinfusion C-reactive protein and bone marrow disease burden, and postinfusion peak ferritin and occurrence of severe cytokine release syndrome, which were used to create the CytoRisk score. In the validation cohort, the CytoRisk score discriminated between patients with and without PSN (area under the curve, 0.90; specificity, 93%; sensitivity, 71%; positive predictive value, 74%; and negative predictive value, 92%). The CytoRisk score may be used to a priori identify patients at highest risk of PSN and overall worse outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Naik S, Selukar S, Talleur AC, et al. Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025. PMID: 40690779. doi:10.1182/bloodadvances.2025016824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。